Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France; Institut de Recherche en Cancérologie de Montpellier, INSERM, Université de Montpellier, Institut Régional du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298 Montpellier Cedex 5, France.
Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France; Nuclear Medicine Department, Montpellier Cancer Institute (ICM), University of Montpellier, 208 Avenue des Apothicaires, 34298 Montpellier Cedex 5, France.
Bioorg Med Chem Lett. 2020 Nov 15;30(22):127527. doi: 10.1016/j.bmcl.2020.127527. Epub 2020 Sep 2.
We describe herein the synthesis of a series of carboplatin derivatives with different functional groups at position 3 of the cyclobutane ring. This pharmacomodulation approach aims at facilitating the vectorisation of these analogues, via their subsequent conjugation to a drug delivery system. Five different derivatives bearing a hydroxy, keto, iodo, azido or amino function at position 3 were synthesised. One of these compounds was coupled to a bifunctional maleimide-containing linker. All compounds were tested in vitro for their cytotoxicity on four different cell lines including two platinum-resistant colorectal cancer cell line (SK-OV-3, HCT116, D3E2, D5B7) using an MTS assay. Overall, the tested compounds were up to six times more potent than carboplatin, especially on D5B7 human colorectal cancer cells. We demonstrated that these modifications led to potent analogues which are compatible with conjugation to a drug delivery system.
我们描述了一系列在环丁烷环 3 位具有不同官能团的卡铂衍生物的合成。这种药物修饰方法旨在通过随后将这些类似物与药物传递系统缀合来促进它们的载体化。合成了五个在 3 位具有羟基、酮基、碘基、叠氮基或氨基的不同衍生物。其中一种化合物与含有双功能马来酰亚胺的接头偶联。所有化合物均在体外使用 MTS 测定法,在四种不同的细胞系(包括两种铂耐药结直肠癌细胞系(SK-OV-3、HCT116、D3E2、D5B7)上测试了它们的细胞毒性。总的来说,测试的化合物比卡铂的效力高 6 倍以上,特别是对 D5B7 人结直肠癌细胞。我们证明了这些修饰导致了与药物传递系统缀合相容的有效类似物。